Euroapi S.A. provided earnings guidance for the Fiscal Year 2026. For the period, the company expects Net Sales to decrease around 10% on a comparable basis compared to 2025 due to the negative impact of portfolio rationalization (?(55) to (60) million negative impact expected in 202615), reduced demand from Sanofi, and the discontinuation of commercial CDMO contracts.